1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 to 70
Sponsor: Other
Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: GC P#02.01.001, NCT00469729
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: NCI
Protocol IDs: CBMTG-0601, NCT00438958
|
|
6.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 2 to 55
Sponsor: NCI, NHLBI
Protocol IDs: 385, BMT CTN 0402, U01 HL069294-05, NCT00406393
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2905, E2905, NCT00843882
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 4 to 21
Sponsor: NCI
Protocol IDs: NCI-01-C-0125F, NCT00020592
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: H8713, NCT00058825
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB001, NCT00089596
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-065, X05175, NCT00369226
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYCC-6898, 6898, NCI-6898, NCT00392353
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 04U.115, NCT00429416
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDX-009, NCT00481871
|
|
17.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: NCI-07-C-0195, 07-C-0195, NCT00520130
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
19.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 100
Sponsor: Other
Protocol IDs: BCM-H-12472, H 12472, BCM-ACHE, NCT00056966
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 17 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARRAY-520-211, NCT00637052
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 20406, NCT00674427
|
|
23.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HCI #26135, NCT00708721
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2007-0634, NCT00790855
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417
|
